Back

국제약품 KOSPI

002720

Suggest a tag

Watch

Notes Naver Finance

Meeting voting results

Annual 2026.03.26

Participation 41.2% Minority 5.3% Max. opposition 0.0% DART

1 제68기(2025.01.01~2025.12.31) 재무제표(이익잉여금 처분계산서 포함) 및 연결재무제표 승인의 건 Approved Approval 100.0%
2 정관변경의 건 Approved Approval 100.0%
3 이사선임의 건 - 사외이사 후보 김용기 Approved Approval 100.0%
4 감사위원이 되는 사외이사 선임의 건 - 후보 구만회 Approved Approval 100.0%
5 감사위원이 되는 사외이사 선임의 건 - 후보 이승훈 Approved Approval 100.0%
6 감사위원 선임의 건 - 후보 김용기 Approved Approval 100.0%
7 이사 보수한도 승인의 건 Approved Approval 100.0%

Previous meeting results

Financial indicators

Market cap

711 × 100M KRW

PBR

0.72

PER

14.2

ROE

6.09%

Dividend yield

0.89%

Debt-to-equity ratio

86.6%

Share price history

Share price

Daily close

Latest close

5-year high

5-year low

Use the period buttons above to adjust the range.

Shareholder distribution

Based on 2025 Annual report (2025-12-31)

Controlling shareholders total

37.89%

Minority shareholders (excl. related parties)

56.71%

Large outside holders (1%+)

5.40% (9 people)

Treasury shares

0.00%

Total shareholders

16,220 people

Annual earnings Trend

Financial statements

Consolidated · includes subsidiaries

국제약품 — Annual Consolidated Financial statements
Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Income statement
Revenue	1,204.6 × 100M KRW	1,224.3 × 100M KRW	1,176.4 × 100M KRW	1,206.8 × 100M KRW	1,233.1 × 100M KRW	1,076.8 × 100M KRW	1,111.2 × 100M KRW	1,303.9 × 100M KRW	1,197.5 × 100M KRW	1,265.8 × 100M KRW	1,353.7 × 100M KRW	1,564.6 × 100M KRW	1,755 × 100M KRW
Operating profit	10.5 × 100M KRW	-14.2 × 100M KRW	21 × 100M KRW	39.7 × 100M KRW	25.6 × 100M KRW	32.9 × 100M KRW	55.7 × 100M KRW	60.4 × 100M KRW	-16.8 × 100M KRW	52.7 × 100M KRW	-19.9 × 100M KRW	67 × 100M KRW	61.8 × 100M KRW
Net income	16.7 × 100M KRW	-69.2 × 100M KRW	-58.8 × 100M KRW	8 × 100M KRW	10.4 × 100M KRW	21.8 × 100M KRW	-47.6 × 100M KRW	21.9 × 100M KRW	-15.6 × 100M KRW	35.4 × 100M KRW	-84.1 × 100M KRW	52.1 × 100M KRW	57 × 100M KRW
Operating margin	0.87%	-1.16%	1.78%	3.29%	2.08%	3.05%	5.01%	4.63%	-1.40%	4.17%	-1.47%	4.28%	3.52%
Balance sheet
Total assets	1,174.3 × 100M KRW	1,175.1 × 100M KRW	1,366.4 × 100M KRW	1,294.6 × 100M KRW	1,316.5 × 100M KRW	1,262.3 × 100M KRW	1,345.9 × 100M KRW	1,456.3 × 100M KRW	1,397.8 × 100M KRW	1,365.9 × 100M KRW	1,632.6 × 100M KRW	1,655.5 × 100M KRW	1,822.8 × 100M KRW
Total liabilities	591 × 100M KRW	666.6 × 100M KRW	681.8 × 100M KRW	619.4 × 100M KRW	638.7 × 100M KRW	575.4 × 100M KRW	736.4 × 100M KRW	751.3 × 100M KRW	712 × 100M KRW	625.1 × 100M KRW	783.1 × 100M KRW	760 × 100M KRW	845.7 × 100M KRW
Total equity	583.3 × 100M KRW	508.5 × 100M KRW	684.6 × 100M KRW	675.2 × 100M KRW	677.8 × 100M KRW	687 × 100M KRW	609.5 × 100M KRW	705 × 100M KRW	685.9 × 100M KRW	740.8 × 100M KRW	849.5 × 100M KRW	895.5 × 100M KRW	977 × 100M KRW
Cash flow statement
Operating cash flow	-	-	-	-	-	-	-	-	-	-	-	-	58.4 × 100M KRW
Investing cash flow	-	-	-	-	-	-	-	-	-	-	-	-	-41.6 × 100M KRW
Financing cash flow	-	-	-	-	-	-	-	-	-	-	-	-	3.4 × 100M KRW
Investment indicators
ROE	2.87%	-13.60%	-8.60%	1.18%	1.53%	3.18%	-7.81%	3.11%	-2.27%	4.78%	-9.91%	5.81%	5.84%
Debt-to-equity ratio	101.33%	131.07%	99.60%	91.73%	94.23%	83.75%	120.81%	106.56%	103.80%	84.39%	92.18%	84.87%	86.56%
Separate total assets	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-
PER	-	-	-	-	-	-	-	-	-	-	-	-	-
PBR	-	-	-	-	-	-	-	-	-	-	-	-	-
Dividend per share	KRW 10	KRW 10	-	KRW 10	KRW 10	KRW 30	-	-	-	-	-	KRW 30	KRW 30
Detailed accounts
Current assets	-	-	665.6 × 100M KRW	-	-	545.6 × 100M KRW	-	-	482 × 100M KRW	-	-	569.7 × 100M KRW	673.8 × 100M KRW
Non-current assets	-	-	700.9 × 100M KRW	-	-	716.8 × 100M KRW	-	-	915.9 × 100M KRW	-	-	1,085.7 × 100M KRW	1,149 × 100M KRW
Current liabilities	-	-	320.4 × 100M KRW	-	-	482 × 100M KRW	-	-	545.2 × 100M KRW	-	-	285.5 × 100M KRW	620.2 × 100M KRW
Non-current liabilities	-	-	361.5 × 100M KRW	-	-	93.4 × 100M KRW	-	-	166.8 × 100M KRW	-	-	474.5 × 100M KRW	225.5 × 100M KRW
Equity attributable to owners	-	-	-	-	-	-	-	-	-	-	-	-	976.9 × 100M KRW
Share capital	-	-	-	-	-	180.6 × 100M KRW	-	-	192.8 × 100M KRW	-	-	211.6 × 100M KRW	211.6 × 100M KRW
Capital surplus	-	-	-	-	-	-	-	-	-	-	-	-	11.1 × 100M KRW
Other equity	-	-	-	-	-	-	-	-	-	-	-	-	147.7 × 100M KRW
Accumulated other comprehensive income	-	-	-	-	-	-	-	-	-	-	-	-	499.8 × 100M KRW
Retained earnings	-	-	71.2 × 100M KRW	-	-	78.7 × 100M KRW	-	-	10.9 × 100M KRW	-	-	54.1 × 100M KRW	106.6 × 100M KRW
Non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-	1,364 × 10,000 KRW

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

국제약품 — Quarterly Consolidated Financial statements
Item	24/3	24/6	24/9	24/12	25/3	25/6	25/9	25/12	26/3	26/6
Income statement
Revenue	375.3 × 100M KRW	376.4 × 100M KRW	396.5 × 100M KRW	416.4 × 100M KRW	415 × 100M KRW	450.2 × 100M KRW	456.3 × 100M KRW	433.4 × 100M KRW	439.8 × 100M KRW	483.2 × 100M KRW
Operating profit	34 × 100M KRW	6.8 × 100M KRW	16.8 × 100M KRW	9.4 × 100M KRW	23 × 100M KRW	35.1 × 100M KRW	19.2 × 100M KRW	-15.4 × 100M KRW	19.7 × 100M KRW	21.3 × 100M KRW
Net income	27.5 × 100M KRW	6 × 100M KRW	11.5 × 100M KRW	7 × 100M KRW	18.6 × 100M KRW	26.7 × 100M KRW	19.2 × 100M KRW	-7.4 × 100M KRW	21.4 × 100M KRW	16.7 × 100M KRW
Operating margin	9.05%	1.82%	4.23%	2.27%	5.55%	7.79%	4.20%	-3.56%	4.48%	4.42%
Balance sheet
Total assets	1,643.2 × 100M KRW	1,594.6 × 100M KRW	1,624.2 × 100M KRW	1,655.5 × 100M KRW	1,643.1 × 100M KRW	1,717.3 × 100M KRW	1,801.2 × 100M KRW	1,822.8 × 100M KRW	1,789.3 × 100M KRW	1,852.1 × 100M KRW
Total liabilities	760.7 × 100M KRW	707.1 × 100M KRW	725.4 × 100M KRW	760 × 100M KRW	735.4 × 100M KRW	783.2 × 100M KRW	848 × 100M KRW	845.7 × 100M KRW	804.2 × 100M KRW	858.4 × 100M KRW
Total equity	882.5 × 100M KRW	887.5 × 100M KRW	898.7 × 100M KRW	895.5 × 100M KRW	907.7 × 100M KRW	934.1 × 100M KRW	953.2 × 100M KRW	977 × 100M KRW	985 × 100M KRW	993.7 × 100M KRW
Cash flow statement
Operating cash flow	23.7 × 100M KRW	-19.2 × 100M KRW	27.1 × 100M KRW	-	17.4 × 100M KRW	34.5 × 100M KRW	49.9 × 100M KRW	-43.4 × 100M KRW	-11.7 × 100M KRW	72.1 × 100M KRW
Investing cash flow	-1.9 × 100M KRW	-9.7 × 100M KRW	-28.7 × 100M KRW	-	-4.5 × 100M KRW	-9,474 × 10,000 KRW	-4.7 × 100M KRW	-31.4 × 100M KRW	-5.5 × 100M KRW	-7.3 × 100M KRW
Financing cash flow	-5,646 × 10,000 KRW	-30.5 × 100M KRW	19.5 × 100M KRW	-	-4,504 × 10,000 KRW	-6.6 × 100M KRW	9.5 × 100M KRW	9,139 × 10,000 KRW	-4,908 × 10,000 KRW	-7.2 × 100M KRW
Investment indicators
Debt-to-equity ratio	86.20%	79.66%	80.72%	84.87%	81.02%	83.85%	88.96%	86.56%	81.64%	86.38%
EPS	-	-	-	-	KRW 91	KRW 131	KRW 94	-	-	KRW 79
Detailed accounts
Current assets	574.8 × 100M KRW	524.9 × 100M KRW	533.3 × 100M KRW	569.7 × 100M KRW	563.9 × 100M KRW	641.3 × 100M KRW	724.5 × 100M KRW	673.8 × 100M KRW	647.2 × 100M KRW	725.1 × 100M KRW
Non-current assets	1,068.4 × 100M KRW	1,069.7 × 100M KRW	1,090.8 × 100M KRW	1,085.7 × 100M KRW	1,079.2 × 100M KRW	1,076 × 100M KRW	1,076.7 × 100M KRW	1,149 × 100M KRW	1,142 × 100M KRW	1,127 × 100M KRW
Current liabilities	551.1 × 100M KRW	492.3 × 100M KRW	235.7 × 100M KRW	285.5 × 100M KRW	231.5 × 100M KRW	283.7 × 100M KRW	610.9 × 100M KRW	620.2 × 100M KRW	592.1 × 100M KRW	636.8 × 100M KRW
Non-current liabilities	209.6 × 100M KRW	214.7 × 100M KRW	489.7 × 100M KRW	474.5 × 100M KRW	503.9 × 100M KRW	499.5 × 100M KRW	237 × 100M KRW	225.5 × 100M KRW	212.1 × 100M KRW	221.6 × 100M KRW
Equity attributable to owners	882.4 × 100M KRW	887.4 × 100M KRW	898.6 × 100M KRW	-	907.6 × 100M KRW	933.9 × 100M KRW	953 × 100M KRW	976.9 × 100M KRW	984.9 × 100M KRW	993.6 × 100M KRW
Share capital	211.6 × 100M KRW	211.6 × 100M KRW	211.6 × 100M KRW	211.6 × 100M KRW	211.6 × 100M KRW	211.6 × 100M KRW	211.6 × 100M KRW	211.6 × 100M KRW	211.6 × 100M KRW	211.6 × 100M KRW
Capital surplus	11.1 × 100M KRW	11.1 × 100M KRW	11.1 × 100M KRW	-	11.1 × 100M KRW	11.1 × 100M KRW	11.1 × 100M KRW	11.1 × 100M KRW	11.1 × 100M KRW	11.1 × 100M KRW
Other equity	115.2 × 100M KRW	115.2 × 100M KRW	115.2 × 100M KRW	-	115.2 × 100M KRW	115.2 × 100M KRW	115.2 × 100M KRW	147.7 × 100M KRW	147.7 × 100M KRW	147.7 × 100M KRW
Accumulated other comprehensive income	503.8 × 100M KRW	503.7 × 100M KRW	503.7 × 100M KRW	-	503.5 × 100M KRW	503.6 × 100M KRW	503.7 × 100M KRW	499.8 × 100M KRW	493.3 × 100M KRW	486.5 × 100M KRW
Retained earnings	40.6 × 100M KRW	45.8 × 100M KRW	57 × 100M KRW	54.1 × 100M KRW	66.2 × 100M KRW	92.4 × 100M KRW	111.5 × 100M KRW	106.6 × 100M KRW	121.2 × 100M KRW	136.7 × 100M KRW
Non-controlling interests	1,075 × 10,000 KRW	1,383 × 10,000 KRW	1,695 × 10,000 KRW	-	1,075 × 10,000 KRW	1,467 × 10,000 KRW	1,768 × 10,000 KRW	1,364 × 10,000 KRW	979 × 10,000 KRW	656 × 10,000 KRW

Income figures cover the quarter, not the year to date. Balance sheet figures are quarter-end balances.

Quarterly cash flow is calculated from changes in cumulative totals.

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

Separate · this company only

국제약품 — Annual Separate Financial statements
Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Income statement
Revenue	1,172.8 × 100M KRW	1,175.2 × 100M KRW	1,116.5 × 100M KRW	1,149.9 × 100M KRW	1,222.9 × 100M KRW	1,063.1 × 100M KRW	1,087.1 × 100M KRW	1,265.1 × 100M KRW	1,157.4 × 100M KRW	1,236 × 100M KRW	1,312.7 × 100M KRW	1,501.8 × 100M KRW	1,705.4 × 100M KRW
Operating profit	18.8 × 100M KRW	-14.5 × 100M KRW	15.6 × 100M KRW	39.1 × 100M KRW	34.1 × 100M KRW	29.8 × 100M KRW	55.9 × 100M KRW	62 × 100M KRW	-17.5 × 100M KRW	55.4 × 100M KRW	-20.4 × 100M KRW	66.3 × 100M KRW	60.2 × 100M KRW
Net income	26.9 × 100M KRW	-74.9 × 100M KRW	-61.7 × 100M KRW	8.2 × 100M KRW	7.1 × 100M KRW	17 × 100M KRW	-49.9 × 100M KRW	24.3 × 100M KRW	-15.5 × 100M KRW	33.4 × 100M KRW	-84.2 × 100M KRW	51.9 × 100M KRW	55.7 × 100M KRW
Operating margin	1.60%	-1.23%	1.40%	3.40%	2.79%	2.80%	5.15%	4.90%	-1.51%	4.48%	-1.56%	4.41%	3.53%
Balance sheet
Total assets	1,173.2 × 100M KRW	1,165.8 × 100M KRW	1,321.8 × 100M KRW	1,288.1 × 100M KRW	1,310.2 × 100M KRW	1,251.1 × 100M KRW	1,331 × 100M KRW	1,440.1 × 100M KRW	1,381.4 × 100M KRW	1,349.9 × 100M KRW	1,615.7 × 100M KRW	1,638.5 × 100M KRW	1,804.6 × 100M KRW
Total liabilities	584.6 × 100M KRW	657.7 × 100M KRW	641.2 × 100M KRW	614.6 × 100M KRW	637.5 × 100M KRW	574 × 100M KRW	733.6 × 100M KRW	745.8 × 100M KRW	706.4 × 100M KRW	621.8 × 100M KRW	779 × 100M KRW	755.9 × 100M KRW	842.3 × 100M KRW
Total equity	588.7 × 100M KRW	508.1 × 100M KRW	680.5 × 100M KRW	673.5 × 100M KRW	672.8 × 100M KRW	677.1 × 100M KRW	597.4 × 100M KRW	694.3 × 100M KRW	675 × 100M KRW	728.1 × 100M KRW	836.8 × 100M KRW	882.6 × 100M KRW	962.3 × 100M KRW
Cash flow statement
Operating cash flow	-	-	-	-	-	-	-	-	-	-	-	-	52.2 × 100M KRW
Investing cash flow	-	-	-	-	-	-	-	-	-	-	-	-	-42.7 × 100M KRW
Financing cash flow	-	-	-	-	-	-	-	-	-	-	-	-	4.6 × 100M KRW
Investment indicators
ROE	4.58%	-14.73%	-9.06%	1.22%	1.06%	2.51%	-8.35%	3.51%	-2.29%	4.59%	-10.06%	5.88%	5.79%
Debt-to-equity ratio	99.30%	129.45%	94.23%	91.27%	94.75%	84.77%	122.79%	107.43%	104.65%	85.39%	93.09%	85.65%	87.53%
Separate total assets	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-
PER	-	-	-	-	-	-	-	-	-	-	-	-	-
PBR	-	-	-	-	-	-	-	-	-	-	-	-	-
Dividend per share	KRW 10	KRW 10	-	KRW 10	KRW 10	KRW 30	-	-	-	-	-	KRW 30	KRW 30
Detailed accounts
Current assets	-	-	627.3 × 100M KRW	-	-	535.9 × 100M KRW	-	-	475.1 × 100M KRW	-	-	559.8 × 100M KRW	661 × 100M KRW
Non-current assets	-	-	694.5 × 100M KRW	-	-	715.2 × 100M KRW	-	-	906.3 × 100M KRW	-	-	1,078.7 × 100M KRW	1,143.6 × 100M KRW
Current liabilities	-	-	280.2 × 100M KRW	-	-	481.2 × 100M KRW	-	-	543.2 × 100M KRW	-	-	282.1 × 100M KRW	617.7 × 100M KRW
Non-current liabilities	-	-	361.1 × 100M KRW	-	-	92.8 × 100M KRW	-	-	163.1 × 100M KRW	-	-	473.8 × 100M KRW	224.6 × 100M KRW
Share capital	-	-	-	-	-	180.6 × 100M KRW	-	-	192.8 × 100M KRW	-	-	211.6 × 100M KRW	211.6 × 100M KRW
Capital surplus	-	-	-	-	-	-	-	-	-	-	-	-	11.1 × 100M KRW
Other equity	-	-	-	-	-	-	-	-	-	-	-	-	149.5 × 100M KRW
Accumulated other comprehensive income	-	-	-	-	-	-	-	-	-	-	-	-	498.3 × 100M KRW
Retained earnings	-	-	68.1 × 100M KRW	-	-	67.4 × 100M KRW	-	-	-2,382 × 10,000 KRW	-	-	40.5 × 100M KRW	91.7 × 100M KRW

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

국제약품 — Quarterly Separate Financial statements
Item	24/3	24/6	24/9	24/12	25/3	25/6	25/9	25/12	26/3	26/6
Income statement
Revenue	-	-	-	-	-	-	-	-	435.7 × 100M KRW	-
Operating profit	-	-	-	-	-	-	-	-	20.5 × 100M KRW	-
Net income	-	-	-	-	-	-	-	-	22.2 × 100M KRW	-
Operating margin	-	-	-	-	-	-	-	-	4.71%	-
Balance sheet
Total assets	-	-	-	-	-	-	-	-	1,772.9 × 100M KRW	-
Total liabilities	-	-	-	-	-	-	-	-	801.9 × 100M KRW	-
Total equity	-	-	-	-	-	-	-	-	971 × 100M KRW	-
Cash flow statement
Operating cash flow	-	-	-	-	-	-	-	-	-13.4 × 100M KRW	-
Investing cash flow	-	-	-	-	-	-	-	-	-7.3 × 100M KRW	-
Financing cash flow	-	-	-	-	-	-	-	-	-2,506 × 10,000 KRW	-
Investment indicators
Debt-to-equity ratio	-	-	-	-	-	-	-	-	82.58%	-
EPS	-	-	-	-	-	-	-	-	-	-
Detailed accounts
Current assets	-	-	-	559.8 × 100M KRW	-	-	-	661 × 100M KRW	634.1 × 100M KRW	-
Non-current assets	-	-	-	1,078.7 × 100M KRW	-	-	-	1,143.6 × 100M KRW	1,138.8 × 100M KRW	-
Current liabilities	-	-	-	282.1 × 100M KRW	-	-	-	617.7 × 100M KRW	590.6 × 100M KRW	-
Non-current liabilities	-	-	-	473.8 × 100M KRW	-	-	-	224.6 × 100M KRW	211.2 × 100M KRW	-
Share capital	-	-	-	211.6 × 100M KRW	-	-	-	211.6 × 100M KRW	211.6 × 100M KRW	-
Capital surplus	-	-	-	-	-	-	-	11.1 × 100M KRW	11.1 × 100M KRW	-
Other equity	-	-	-	-	-	-	-	149.5 × 100M KRW	149.5 × 100M KRW	-
Accumulated other comprehensive income	-	-	-	-	-	-	-	498.3 × 100M KRW	491.8 × 100M KRW	-
Retained earnings	-	-	-	40.5 × 100M KRW	-	-	-	91.7 × 100M KRW	107 × 100M KRW	-

Income figures cover the quarter, not the year to date. Balance sheet figures are quarter-end balances.

Quarterly cash flow is calculated from changes in cumulative totals.

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

Legacy summaries and estimates; may include data with unverified accounting scope.

국제약품 — Annual Legacy summary & estimates Financial statements
Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023 Consolidated	2024 Consolidated	2025 Consolidated
Income statement
Revenue	1,204.6 × 100M KRW	1,224.3 × 100M KRW	1,176.4 × 100M KRW	1,206.8 × 100M KRW	1,233.1 × 100M KRW	1,076.8 × 100M KRW	1,111.2 × 100M KRW	1,303.9 × 100M KRW	1,197.5 × 100M KRW	1,265.8 × 100M KRW	1,353.7 × 100M KRW	1,564.6 × 100M KRW	1,755 × 100M KRW
Operating profit	10.5 × 100M KRW	-14.2 × 100M KRW	21 × 100M KRW	39.7 × 100M KRW	25.6 × 100M KRW	32.9 × 100M KRW	55.7 × 100M KRW	60.4 × 100M KRW	-16.8 × 100M KRW	52.7 × 100M KRW	-19.9 × 100M KRW	67 × 100M KRW	61.8 × 100M KRW
Net income	16.7 × 100M KRW	-69.2 × 100M KRW	-58.8 × 100M KRW	8 × 100M KRW	10.4 × 100M KRW	21.8 × 100M KRW	-47.6 × 100M KRW	21.9 × 100M KRW	-15.6 × 100M KRW	35.4 × 100M KRW	-84.1 × 100M KRW	52.1 × 100M KRW	57 × 100M KRW
Operating margin	0.87%	-1.16%	1.78%	3.29%	2.08%	3.05%	5.01%	4.63%	-1.40%	4.17%	-1.47%	4.28%	3.52%
Balance sheet
Total assets	-	-	-	-	-	-	-	-	-	-	1,632.6 × 100M KRW	1,655.5 × 100M KRW	1,822.8 × 100M KRW
Total liabilities	591 × 100M KRW	666.6 × 100M KRW	681.8 × 100M KRW	619.4 × 100M KRW	638.7 × 100M KRW	575.4 × 100M KRW	736.4 × 100M KRW	751.3 × 100M KRW	712 × 100M KRW	625.1 × 100M KRW	783.1 × 100M KRW	760 × 100M KRW	845.7 × 100M KRW
Total equity	583.3 × 100M KRW	508.5 × 100M KRW	684.6 × 100M KRW	675.2 × 100M KRW	677.8 × 100M KRW	687 × 100M KRW	609.5 × 100M KRW	705 × 100M KRW	685.9 × 100M KRW	740.8 × 100M KRW	849.5 × 100M KRW	895.5 × 100M KRW	977 × 100M KRW
Investment indicators
ROE	2.87%	-13.60%	-8.60%	1.18%	1.53%	3.18%	-7.81%	3.11%	-2.27%	4.78%	-9.91%	5.81%	5.84%
Debt-to-equity ratio	101.33%	131.07%	99.60%	91.73%	94.23%	83.75%	120.81%	106.56%	103.80%	84.39%	92.18%	84.87%	86.56%
Separate total assets	-	-	-	-	-	-	-	-	-	-	1,615.7 × 100M KRW	1,638.5 × 100M KRW	1,804.6 × 100M KRW
EPS	-	-	-	KRW 46	KRW 64	KRW 128	KRW -259	KRW 120	KRW -85	KRW 168	KRW -398	KRW 246	KRW 269
PER	-	-	-	-	-	-	-	-	-	31.24×	-14.89×	20.57×	15.97×
PBR	-	-	-	-	-	-	-	-	-	1.44	1.41	1.15	0.93
Dividend per share	KRW 10	KRW 10	-	KRW 10	KRW 10	KRW 30	-	-	-	-	-	KRW 30	KRW 30

국제약품 — Quarterly Legacy summary & estimates Financial statements
Item	24/3 Consolidated	24/6 Consolidated	24/9 Consolidated	24/12 Consolidated	25/3 Consolidated	25/6 Consolidated	25/9 Consolidated	25/12 Consolidated	26/3 Consolidated	26/6 Consolidated
Income statement
Revenue	375.3 × 100M KRW	376.4 × 100M KRW	396.5 × 100M KRW	416.4 × 100M KRW	415 × 100M KRW	450.2 × 100M KRW	456.3 × 100M KRW	433.4 × 100M KRW	439.8 × 100M KRW	483.2 × 100M KRW
Operating profit	34 × 100M KRW	6.8 × 100M KRW	16.8 × 100M KRW	9.4 × 100M KRW	23 × 100M KRW	35.1 × 100M KRW	19.2 × 100M KRW	-15.4 × 100M KRW	19.7 × 100M KRW	21.3 × 100M KRW
Net income	27.5 × 100M KRW	6 × 100M KRW	11.5 × 100M KRW	7 × 100M KRW	18.6 × 100M KRW	26.7 × 100M KRW	19.2 × 100M KRW	-7.4 × 100M KRW	21.4 × 100M KRW	16.7 × 100M KRW
Operating margin	9.05%	1.82%	4.23%	2.27%	5.55%	7.79%	4.20%	-3.56%	4.48%	4.42%
Balance sheet
Total assets	1,643.2 × 100M KRW	1,594.6 × 100M KRW	1,624.2 × 100M KRW	1,655.5 × 100M KRW	1,643.1 × 100M KRW	1,717.3 × 100M KRW	1,801.2 × 100M KRW	1,822.8 × 100M KRW	1,789.3 × 100M KRW	1,852.1 × 100M KRW
Total liabilities	760.7 × 100M KRW	707.1 × 100M KRW	725.4 × 100M KRW	760 × 100M KRW	735.4 × 100M KRW	783.2 × 100M KRW	848 × 100M KRW	845.7 × 100M KRW	804.2 × 100M KRW	858.4 × 100M KRW
Total equity	882.5 × 100M KRW	887.5 × 100M KRW	898.7 × 100M KRW	895.5 × 100M KRW	907.7 × 100M KRW	934.1 × 100M KRW	953.2 × 100M KRW	977 × 100M KRW	985 × 100M KRW	993.7 × 100M KRW
Investment indicators
Debt-to-equity ratio	86.20%	79.66%	80.72%	84.87%	81.02%	83.85%	88.96%	86.56%	81.64%	86.38%
EPS	-	-	-	-	KRW 91	KRW 131	KRW 94	-	-	KRW 79

Income figures cover the quarter, not the year to date. Balance sheet figures are quarter-end balances.

Property holdings

Total book value

856 × 100M KRW

Total assessed land value

830 × 100M KRW

Ratio to market cap

120.3%

Land

1 records

Buildings

1 records

Category	Location	Use	Area	Book value	Assessed land value
Land Unverified	안산공장	-	-	721 × 100M KRW	721 × 100M KRW
Building Unverified	안산공장	-	-	96 × 100M KRW	-
투자부동산 Unverified	본사 건물	임대용	-	39 × 100M KRW	110 × 100M KRW

Ownership structure

Listed subsidiary stake value 14 × 100M KRW (Sum of market cap × ownership)

Is a listed company shown as unlisted?

Corporate shareholders

Corporate and institutional holders identified in collected disclosures. This is not a complete shareholder register. Reporting-group holdings may overlap with individual holdings.

Articles of incorporation analysis

Analysis date 2026.07.30 10:25 | Last amended 2024.03.29

Unverified Original articles of incorporation

주주친화

동등배당: 배당기준일 현재 발행된 동종 주식에 대하여 발행일과 관계없이 모두 동등하게 배당한다 (제9조의4)

주주비친화

집중투표제 명시적 배제: 2인 이상의 이사를 선임하는 경우에도 상법 제382조의2의 집중투표제를 적용하지 않아 소수주주의 이사 선임 기회를 제한한다 (제30조④)
이사 임기 3년 고정: 일반 이사의 임기를 상법상 최장 수준인 3년으로 정하여 이사회 교체에 장기간이 소요될 수 있다. 사외이사의 임기는 2년이다 (제31조①)
이사회 결의에 의한 120억원 전환사채 제3자 발행: 주주 외의 자에게 최대 120억원의 전환사채를 발행할 수 있어 경영권 분쟁 시 우호지분 확보와 기존 주주 희석 수단으로 활용될 수 있다 (제14조의2)
이사회 결의에 의한 120억원 신주인수권부사채 제3자 발행: 주주 외의 자에게 최대 120억원의 신주인수권부사채를 발행할 수 있다 (제15조)
대규모 제3자 신주배정 권한: 이사회가 일반공모, 긴급 자금조달, 기술도입 등의 사유로 발행주식총수의 최대 50% 범위에서 주주 외의 자에게 신주를 배정할 수 있어 상당한 지분 희석 가능성이 있다 (제9조②)
이사 책임감경 조항: 주주총회 결의로 일반 이사는 최근 1년간 보수액의 6배, 사외이사는 3배를 초과하는 손해배상책임을 면제할 수 있어 책임 추궁의 실효성을 약화시킬 수 있다 (제33조의3)

기타 주목 조항

감사위원회 구성: 감사위원회는 3명 이상의 이사로 구성하고 그중 3분의 2 이상을 사외이사로 하며, 감사위원이 되는 이사 1명 이상을 다른 이사와 분리하여 선임한다 (제38조의2)
우선주 전환: 우선주식은 발행일부터 10년이 지나면 보통주식으로 전환되며, 미지급 배당이 있으면 배당 완료 시까지 존속기간이 연장된다 (제7조의2⑦)
배당기준일: 이사회가 배당받을 주주를 확정하기 위한 기준일을 정할 수 있고 그 기준일 2주 전에 공고한다 (제42조②)

Board of directors

Number of directors

3–10 people

Director term

3 years (Fixed)

Staggered board

None

Cumulative voting

Separate chair and CEO

Gender diversity requirement

Director liability limitation

Exemption above 6.0×

Auditors

Number of auditors

At least 3 people

Auditor term

Shareholder meetings and dividends

Meeting notice period

14 days

Written voting

Electronic voting

Dividend record date

이사회 결의로 배당받을 주주를 확정하기 위한 기준일을 정할 수 있으며, 기준일 2주 전에 공고한다.

Third-party allotment limit by board resolution alone

Convertible bonds (CB)

120 × 100M KRW

Bonds with warrants (BW)

120 × 100M KRW

Compensation basis

Director: 이사의 보수는 주주총회 결의로 정한다.
Retirement payments: 이사의 퇴직금은 주주총회 결의를 거친 임원퇴직금지급규정에 따라 지급한다.

Executive compensation

Based on 2025 Annual report

Total compensation

64 × 100M KRW

Executives

6 people

Average per executive

11 × 100M KRW

Total dividends

6 × 100M KRW

Compensation / dividends

10.1×

Controlling shareholders

Name	Relationship	Age	Ownership
우경	특수관계 (계열회사)	-	23.96%
남영우	Self	-	8.58%
남태훈	특수관계 (자)	-	2.12%
(재)효림장학재단	특수관계(재단)	-	1.70%
남충우	동생	-	1.07%
김성규	특수관계 (임원)	-	0.27%
김영관	특수관계 (임원)	-	0.16%
박병식	이모부	-	0.03%
남철우	동생	-	0.00%
오보석	특수관계 (임원)	-	0.00%

Holders of 5% or more

Holder	Holding ratio	Shares held	Change in ownership	Reason for filing	Report type	Filing date
남영우	37.95%	8,030,205	+0.02%	임원주식매수, 주식담보 계약연장	일반	2026-08-11
남영우	37.93%	8,026,659	+0.06%	임원주식매수, 주식담보 계약연장	일반	2026-05-29
남영우	37.87%	8,014,009	+0.01%	임원주식매수, 주식담보 계약연장	일반	2026-02-11
남영우	37.86%	8,012,009	0.00%	주식담보 계약연장	일반	2025-08-13
남영우	37.86%	8,012,009	0.00%	주식담보계약변경	일반	2025-05-29
남영우	37.86%	8,012,009	0.00%	주식담보계약변경	일반	2025-05-15
남영우	37.86%	8,012,009	0.00%	주식담보계약변경	일반	2025-03-04
남영우	37.86%	8,012,009	0.00%	주식담보계약변경	일반	2025-02-19
남영우	37.86%	8,012,009	0.00%	주식담보계약변경	일반	2025-01-21
남영우	37.86%	8,012,009	0.00%	주식담보계약변경	일반	2024-12-16
남영우	37.86%	8,012,009	0.00%	임원 장내주식매수, 주식담보계약연장	일반	2024-12-05
남영우	37.86%	8,010,934	0.00%	주식담보계약 변경	일반	2024-11-21
한국증권금융	4.09%	865,719	-0.61%	신용공여에 따른 담보권 신규취득 및 변동	약식	2024-10-08
남영우	37.86%	8,010,934	0.00%	주식담보계약 신규, 해지, 변경	일반	2024-09-13
남영우	37.86%	8,010,934	0.00%	주식담보계약 만기연장	일반	2024-09-06
남영우	37.86%	8,010,934	0.00%	주식담보계약일부해지 및 신규계약	일반	2024-07-26
남영우	37.86%	8,010,934	0.00%	주식담보계약해지 및 신규계약	일반	2024-07-11
남영우	37.86%	8,010,934	0.00%	주식담보계약연장	일반	2024-06-11
남영우	37.86%	8,010,934	0.00%	주식담보계약변경	일반	2024-03-08

Auditors

Analysis date 2026.08.26 13:07

Auditor	Type	Term start	Term end	Tenure	D-day
김용기	Audit committee member	2026.01.01	2028.03.26	1 years	D-508
구만회	Audit committee member	2026.01.01	2028.03.26	1 years	D-508
이승훈	Audit committee member	2026.01.01	2028.03.26	1 years	D-508

Executives

Name	Position	Category	Age	Term end
구만회	이사	독립이사	Age 69	D-508
이승훈	이사	독립이사	Age 67	D-508
김성규	전무	Inside director	Age 62	D-510
김영관	부사장	Inside director	Age 60	D-145
김용기	이사	독립이사	Age 60	D-508
차명회	상무보	미등기	Age 60	-
최해성	상무	미등기	Age 59	-
김영훈	상무보	미등기	Age 57	-
오보석	상무	미등기	Age 57	-
박진옥	상무보	미등기	Age 55	-
권오용	상무보	미등기	Age 54	-
김상룡	상무보	미등기	Age 50	-
남태훈	부회장	Inside director	Age 46	D-145

DART disclosures

Loading disclosures…

Activism & governance

Ownership changes Importance 3 2026.10.12 10:00

국제약품 최대주주 변경과 남태훈 부회장 지분 승계

국제약품의 최대주주 변경 공시와 남태훈 부회장의 지분 변동이 이뤄졌다. 기사는 국제약품 최대주주인 우경의 소유권이 부친에게 집중돼 있고 계열사 간 사업·재무 관계도 이어지고 있다고 전했다.

Shareholder perspective 최대주주 변경과 가족 간 지분 이전은 국제약품의 지배구조와 의결권 구도에 영향을 줄 수 있다.

국제약품 KOSPI

Meeting voting results Collapse Meeting voting results

Financial indicators Collapse Financial indicators

Share price history 10 years 5 years 3 years 1 year 3 months 1 week Collapse Share price history

Shareholder distribution Collapse Shareholder distribution

Annual earnings Trend Collapse Annual earnings

Financial statements Collapse Financial statements

Consolidated

Separate

Legacy summary & estimates

Property holdings Collapse Property holdings

Ownership structure Collapse Ownership structure

Corporate shareholders Collapse Corporate shareholders

Articles of incorporation analysis Collapse Articles of incorporation analysis

주주친화

주주비친화

기타 주목 조항

Board of directors

Auditors

Shareholder meetings and dividends

Third-party allotment limit by board resolution alone

Compensation basis

Executive compensation Collapse Executive compensation

Controlling shareholders Collapse Controlling shareholders

Holders of 5% or more Collapse Holders of 5% or more

Auditors Collapse Auditors

Executives Collapse Executives

DART disclosures Collapse DART disclosures

Activism & governance Collapse Activism & governance

국제약품 최대주주 변경과 남태훈 부회장 지분 승계

Meeting voting results

Financial indicators

Share price history

Shareholder distribution

Annual earnings Trend

Financial statements

Property holdings

Ownership structure

Corporate shareholders

Articles of incorporation analysis

Executive compensation

Controlling shareholders

Holders of 5% or more

Auditors

Executives

DART disclosures

Activism & governance